Koers Takeda Pharmaceutical Company Limited Mexican S.E.
Aandelen
TAK N
US8740602052
Farmaceutische producten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
240,5 MXN | -1,84% | -.--% | +0,33% |
16/05 | Takeda Canada rondt LOI-fase af voor behandeling van cytomegalovirus na transplantatie | MT |
15/05 | Dengue-vaccin van Takeda Pharmaceutical geprekwalificeerd door WHO | MT |
Omzet 2024 | 4.264 mld. 27,15 mld. 454 mld. 25,04 mld. | Omzet 2025 * | 4.108 mld. 26,15 mld. 438 mld. 24,12 mld. | Marktkapitalisatie | 6.486 mld. 41,3 mld. 691 mld. 38,09 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 144 mld. 917 mln. 15,35 mld. 846 mln. | Nettowinst (verlies) 2025 * | 136 mld. 864 mln. 14,46 mld. 797 mln. | EV/omzet 2024 | 1,54 x |
Nettoschuld 2024 * | 3.771 mld. 24,01 mld. 402 mld. 22,14 mld. | Nettoschuld 2025 * | 4.204 mld. 26,77 mld. 448 mld. 24,69 mld. | EV/omzet 2025 * | 2,6 x |
K/w-verhouding 2024 |
45,4
x | K/w-verhouding 2025 * |
45,8
x | Werknemers | 49.095 |
Dividendrendement 2024 * |
4,55% | Dividendrendement 2025 * |
4,61% | Vrij verhandelbaar | 99,12% |
Recentste transcriptie over Takeda Pharmaceutical Company Limited
1 dag | -1,84% | ||
3 maanden | -1,84% | ||
6 maanden | +0,33% | ||
Lopend jaar | +0,33% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01-04-14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-02-22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01-01-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 01-06-16 | |
Ian Clark
BRD | Director/Board Member | 62 | 01-01-19 |
Steven Gillis
BRD | Director/Board Member | 71 | 01-01-19 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,51% | 728 mld. | |
+33,05% | 603 mld. | |
-6,23% | 360 mld. | |
+18,78% | 332 mld. | |
+1,35% | 279 mld. | |
+16,00% | 244 mld. | |
+8,09% | 207 mld. | |
-5,77% | 205 mld. | |
+6,19% | 164 mld. |
- Beurs
- Aandelen
- Koers 4502
- Koers TAK N